GHRP-2 Acetate 5mg

Research

Scientific Research on GHRP-2 (Growth Hormone Releasing Peptide-2)
GHRP-2 (Growth Hormone Releasing Peptide-2), also known as pralmorelin, is a synthetic hexapeptide belonging to the class of growth hormone secretagogues (GHS). Developed as an agonist of the ghrelin receptor (GHS-R1a), it has the capacity to stimulate endogenous growth hormone (GH) secretion.
Structurally composed of six synthetic amino acids, it exhibits high secretagogue potency when administered parenterally. Unlike GHRH (Growth Hormone Releasing Hormone), GHRP-2 acts through a mechanism independent of the classical hypothalamic GHRH pathway, although synergy exists between both pathways.

Mechanism of Action and Inhibition

GHRP-2 acts as an agonist of the GHS-R1a receptor (Growth Hormone Secretagogue Receptor type 1a), a G protein-coupled receptor (GPCR) primarily expressed in:

• Anterior pituitary
• Hypothalamus
• Central nervous system

Molecular mechanism:

• Binding to GHS-R1a
• Activation of Gq protein
• Stimulation of phospholipase C (PLC)
• Increase in IP3 and DAG
• Elevation of intracellular calcium
• Stimulation of GH secretion by somatotroph cells

Additionally, GHRP-2 may:

• Reduce somatostatin activity (indirect effect)
• Act synergistically with GHRH
• Discreetly increase prolactin and ACTH secretion in some models

It does not act as an enzymatic inhibitor; its effect is predominantly receptor-dependent agonist.

Scientifically Investigated Metabolic Impacts

GHRP-2 administration results in acute GH increases and subsequent IGF-1 elevation (depending on exposure duration).
Metabolic effects observed in experimental studies include:
Protein metabolism

• Indirect stimulation of protein synthesis (via GH/IGF-1)

Lipid metabolism

• Increased lipolysis
• Reduction of adipose mass (with prolonged exposure)

Carbohydrate metabolism

• Potential reduction in insulin sensitivity (via GH increase)
• Transient blood glucose elevation in some models

Also described:

• Appetite stimulation (via ghrelin receptor activation)
• Potential influence on hypothalamus-pituitary-adrenal axis

Metabolic effects are dose-, frequency-, and baseline somatotrophic axis-dependent.

Investigation in Oncological Models

GH/IGF-1 axis activation raises interest in oncology due to IGF-1-associated proliferative potential.
Experimental models indicate chronic GH axis stimulation may:

• Activate proliferative pathways (PI3K/Akt/mTOR)
• Modulate cell survival
• Influence angiogenesis

However, there is no consolidated evidence of GHRP-2 investigation as an antitumor agent. Its oncological interest relates primarily to safety and implications of sustained IGF-1 increases.

Pharmacokinetic Considerations in Research

GHRP-2 exhibits:

• Subcutaneous or intravenous administration in experimental protocols
• Short plasma half-life
• Rapid GH peak post-administration (typically within 15–60 minutes)
• Rapid clearance by systemic peptidases

Its biological effect is pulsatile, partially mimicking physiological GH secretion when administered intermittently.
Response may diminish with continuous administration due to receptor desensitization.

Other Important Existing Research Relationships

• Studies on GH deficiency
• Diagnostic evaluation of somatotrophic axis
• Aging and sarcopenia investigation
• Interaction with ghrelin and appetite regulation
• Potential sleep modulation (GH predominantly secreted during deep sleep)
  GHRP-2 is frequently used in research to test pituitary functional integrity.

Final Considerations

GHRP-2 is a synthetic hexapeptide GH secretagogue acting through GHS-R1a receptor activation, stimulating endogenous growth hormone release. Its mechanism differs from GHRH, enabling pharmacological synergy.
In research context, it is relevant for somatotrophic axis investigation, energy metabolism, and neuroendocrine regulation. However, prolonged GH/IGF-1 axis activation requires cautious analysis regarding potential systemic proliferative implications.

Pralmorelin; 158861-67-7; GHRP-2; KP-102; Pralmorelina; ...
CID compound: 6918245
MF: C45H55N9O6
MW: 818.0 g/mol
IUPAC name: (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
SMILES: CC@HN
InChIKey: HRNLPPBUBKMZMT-RDRUQFPZSA-N
Creation date: 2006-07-28 - PubChem

References

Bowers, C. Y., Momany, F. A., Reynolds, G. A., & Hong, A. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537–1545. https://doi.org/10.1210/endo-114-5-1537
Smith, R. G., Van der Ploeg, L. H., Howard, A. D., et al. (1997). Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews, 18(5), 621–645. https://doi.org/10.1210/edrv.18.5.0312
Kojima, M., Hosoda, H., Date, Y., et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656–660. https://doi.org/10.1038/45230
Liu, J., Prudom, C. E., Nass, R., et al. (2007). Novel ghrelin assays provide evidence for independent regulation of ghrelin acylation and secretion in healthy young men. Journal of Clinical Endocrinology & Metabolism, 92(5), 1980–1987. https://doi.org/10.1210/jc.2006-1597

Scientific Reviewer
Content reviewed by Dr. Ky H. Le, MD. Dr. Ky H. Le is a family physician in Aiea, Hawaii. He received his medical degree from St. George's University School of Medicine and has been practicing for over 20 years. He has expertise in treating obesity, diabetes, hypertension, and high blood pressure, among other conditions—see all areas of specialization. Dr. Ky H. Le accepts Medicare, Aetna, Humana, Blue Cross, United Healthcare.
Ref.: https://health.usnews.com/doctors/ky-le-371599#expertise